SND1 Promotes Radioresistance in Cervical Cancer Cells by Targeting the DNA Damage Response
Cancer Biotherapy and Radiopharmaceuticals · 2024-08 · 39 (6) · 425-434
DOI: 10.1089/cbr.2021.0371 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, online erschienen am 16.08.2024. Verfasst von Xiao Fu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Immune Microenvironment and Disease, Ministry of Education, Tianjin Medical University, Tianjin, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Radiation Tolerance, DNA Damage, Endonucleases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
Background
Radiotherapy is one of the most effective therapeutic strategies for cervical cancer patients, although radioresistance-mediated residual and recurrent tumors are the main cause of treatment failure. However, the mechanism of tumor radioresistance is still elusive. DNA damage response pathways are key determinants of radioresistance. The purpose of this study was to investigate the role and mechanism of SND1 in radioresistance of cervical cancer.
Methods
A stable HeLa cell line with SND1 knockout (HeLa-KO) was generated through a modified CRISPR/Cas9 double-nicking gene editing system. The stable CaSki cell lines with SND1 knockdown (CaSki-Ctrl, CaSki-SND1-sh-1, CaSki-SND1-sh-2) were constructed through lentivirus transfection with the pSil-SND1-sh-1 and pSil-SND1-sh-2 plasmids.
Results
It was observed that SND1 deficiency significantly increased the radiosensitivity of cervical cancer cells. It was also found that silencing SND1 promotes radiation-induced apoptosis. Significantly, the cells with a loss of SND1 function exhibited inefficient ataxia telangiectasia mutated pathway activation, subsequently impairing DNA repair and G2/M checkpoint arrest. In addition, threonine 103 is an important phosphorylation site of SND1 under DNA damaging stress.
Conclusion
Collectively, the results of this study reveal a potent radiosensitizing effect of silencing SND1 or T103 mutation on cervical cancer cells, providing novel insights into potential therapeutic strategies for cervical cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Immune Microenvironment and Disease, Ministry of Education, Tianjin Medical University, Tianjin, China.
- Key Laboratory of Cellular and Molecular Immunology in Tianjin, Department of Biochemistry and Molecular Biology, Excellent Talent Project, Tianjin Medical University, Tianjin, China.
- Department of Immunology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
- Flow Cytometry Lab, Department of Hematopathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
- Clinical Laboratory, Tianjin Medical University General Hospital, Tianjin, China.
ORCID-Profile: Xiao Fu
Zitieren
APA
Fu, X., Duan, Z., Lu, X., Zhu, Y., Ren, Y., Zhang, W., Sun, X., Ge, L., & Yang, J. (2024). SND1 Promotes Radioresistance in Cervical Cancer Cells by Targeting the DNA Damage Response. Cancer Biotherapy and Radiopharmaceuticals, 39(6), 425-434. https://doi.org/10.1089/cbr.2021.0371
Vancouver
Fu X, Duan Z, Lu X, Zhu Y, Ren Y, Zhang W, et al. SND1 Promotes Radioresistance in Cervical Cancer Cells by Targeting the DNA Damage Response. Cancer Biotherapy and Radiopharmaceuticals. 2024;39(6):425-434. doi:10.1089/cbr.2021.0371
BibTeX
@article{Fu2024,
author = {Fu, Xiao and Duan, Zhongchao and Lu, Xin and Zhu, Yingyu and Ren, Yuanyuan and Zhang, Wei and Sun, Xiaoming and Ge, Lin and Yang, Jie},
title = {SND1 Promotes Radioresistance in Cervical Cancer Cells by Targeting the DNA Damage Response},
journal = {Cancer Biotherapy and Radiopharmaceuticals},
year = {2024},
volume = {39},
number = {6},
pages = {425--434},
doi = {10.1089/cbr.2021.0371}
}
EUVIMED